NasdaqGM:OCSPharmaceuticals
Assessing Oculis Holding (OCS) Valuation As DIAMOND Phase 3 Trials Reach Key Completion Milestone
Why the DIAMOND program milestone matters for Oculis Holding
Oculis Holding (NasdaqGM:OCS) reported that the final patients have completed study visits in both pivotal Phase 3 DIAMOND trials of OCS-01 for diabetic macular edema, moving the program toward key late stage readouts.
The company plans to share topline data from these registrational studies in June, with a potential new drug application submission targeted for the fourth quarter of 2026, subject to trial outcomes and regulatory...